ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,00%
Bitcoin
60.773,66
-0,04%
Brent Oil
82,585
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) Notícias

IGC

IGC Pharma (IGC)

IGC Pharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:AMEX:IGC
DataHoraFonteTítuloCódigoCompanhia
16/04/202408:00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202410:00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
26/03/202416:00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
20/03/202412:00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
20/03/202408:00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
12/03/202416:00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
28/02/202415:00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
23/02/202414:01Business WireIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetAMEX:IGCIGC Pharma Inc
16/02/202421:05Business WireIGC Pharma Reports Third Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
14/02/202418:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
01/02/202411:20Business WireIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
31/01/202418:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
23/01/202411:20Business WireIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’sAMEX:IGCIGC Pharma Inc
17/01/202411:20Business WireIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s TrialAMEX:IGCIGC Pharma Inc
09/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
29/12/202318:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
19/12/202311:20Business WirePatent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’sAMEX:IGCIGC Pharma Inc
13/12/202311:30Business WireIGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024AMEX:IGCIGC Pharma Inc
06/12/202310:30Business WireIGC Pharma Announces Collaboration to Integrate AI into Clinical TrialsAMEX:IGCIGC Pharma Inc
21/11/202310:30Business WireIGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesAMEX:IGCIGC Pharma Inc
13/11/202310:00Business WireIGC Pharma Reports Second Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
27/10/202318:21Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
19/10/202316:30Business WireIGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyAMEX:IGCIGC Pharma Inc
21/08/202315:30Business WireIGC Announces Results of its 2023 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
14/08/202309:30Business WireIGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsAMEX:IGCIGC Pharma Inc
02/08/202309:30Business WireIGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto RicoAMEX:IGCIGC Pharma Inc
26/07/202318:26Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:IGCIGC Pharma Inc
18/07/202306:22Business WireIGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International ConferenceAMEX:IGCIGC Pharma Inc
12/07/202309:44Business WireIGC Reports Financial Results for Fiscal Year Ended March 31, 2023AMEX:IGCIGC Pharma Inc
07/07/202317:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:IGCIGC Pharma Inc
 Apresentando as notícias mais relevantes sobre:AMEX:IGC

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
YDUQ3
ESTACIO PART ON
BOV
UNIP6
UNIPAR PNB
BOV
COGN3
COGNA ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AERI3
Aeris Industria E Comerc... ON
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados